Phylodynamic Analysis and Implication of HCV Genotype 4 Variability on Antiviral Drug Response and T-Cell Recognition
Therapies for HCV care could change the prevalence and the geographic distribution of genotypes due to differences in Sustained Virologic Response (SVR). In this scenario, uncommon genotypes/subtypes, such as genotype 4, could spread from high-risk groups, replacing genotypes eradicated by antiviral...
Main Authors: | Giuseppina Maria Elena Colomba, Noemi Urone, Vito di Marco, Donatella Ferraro |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/12/12/1363 |
Similar Items
-
Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients
by: Mariantonietta Di Stefano, et al.
Published: (2021-09-01) -
HCV cure for everyone or which challenges remain?
by: Jürgen Kurt Rockstroh
Published: (2015-04-01) -
Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens
by: Ghias Un Nabi Tayyab, et al.
Published: (2020-04-01) -
Time and Mode of Epidemic HCV-2 Subtypes Spreading in Europe: Phylodynamics in Italy and Albania
by: Erika Ebranati, et al.
Published: (2021-02-01) -
Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
by: Nathalie Alazard-Dany, et al.
Published: (2019-01-01)